European Journal of Cancer
Volume 45, Issue 1 , Pages 12-18 , January 2009

Current perspective – Trastuzumab

  • Peter S. Hall

      Affiliations

    • University of Leeds, UK
    • Tel.: +44 7867558406.
    • ,
  • David A. Cameron

      Affiliations

    • NCRN Coordinating Centre, University of Leeds, 24 Hyde Terrace, Leeds LS2 9LN, UK
    • Corresponding Author InformationCorresponding author: Tel.: +44 1133438033; fax: +44 1133432242.

Received 8 October 2008 ,Accepted 16 October 2008.

References 

  1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182
  2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–712
  3. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantifation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13(1):63–72
  4. Hynes NE, Gerber HA, Saurer S, Groner B. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem. 1989;39(2):167–173
  5. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18(6):977–984
  6. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10(17):5650–5655
  7. Antonio C, Wolff MEHH, Jared N, et al., American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. ASCO Clinical Practice Guidelines 2007.
  8. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–726
  9. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–2648
  10. Pegram MD, Konecny GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of Trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96(10):739–749
  11. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of Trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–4274
  12. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792
  13. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722–2730
  14. Coordinating author for the ESMO Guidelines Working Group: V. V. Kalaja. Recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii9–11.
  15. Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy. 2008;87(2):146–159
  16. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004;5(1):52–58[discussion 59–62]
  17. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer. 2003;4(2):120–125
  18. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22(6):1063–1070
  19. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie. 2005;28(11):582–586
  20. Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist. 2006;11(4):318–324
  21. Bachelot T, Mauriac L, Delcambre C, et al. Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression. J Clin Oncol. 2007;25(Suppl. 18):1094
  22. Yardley DA, Kaufman PA, Mayer M, et al. RegistHER: patient characteristics, treatment patterns, and preliminary outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol. 2007;25(Suppl. 18):21007
  23. Von Minckwitz G, Zielinski C, Maarteense E, et al. Capecitabine vs. capecitabine+trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05). J Clin Oncol. 2008;26(Suppl. 15):1025
  24. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743
  25. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008. [Epub ahead of print].
  26. Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol. 1988;8(12):5570–5574
  27. Baselga J, Cameron D, Miles D, et al. Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol. 2007;25(Suppl. 18):1004
  28. Moulder SL, O’Neill A, Arteaga C, et al. Final results of ECOG1100: a phase I/II study of combined blockade of the ErbB receptor network in patients with HER2-overexpressing metastatic breast cancer (MBC). J Clin Oncol. 2007;25(Suppl. 18):1033
  29. Modi S SA, Linden HM, Sugarman S, et al. Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients (pts) with HER2-positive breast cancer: preliminary results. Breast Cancer Treat Res. 2006;100(Suppl. 1):abstr 1102
  30. Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10(5):1706–1716
  31. Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene. 2000;19(31):3460–3469
  32. Pegram M CD, Dichmann RA, Tan-Chiu E, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Research and Treatment. 2006;100(Supp1):abstr 301
  33. Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol. 2008;26(Suppl. 15):1016
  34. Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with Trastuzumab: incidence, survival, and risk factors. Oncologist. 2007;12(7):766–773
  35. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–2977
  36. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer. 2004;40(3):379–382
  37. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Brit J Cancer. 2004;91(4):639–643
  38. Heinrich BBO, Siekiera W, Raab G, Heinemann V. Development of brain metastasis in metastatic breast cancer (MBC) responding to treatment with trastuzumab. Proc Am Soc Clin Oncol. 2003;22;abstr 147
  39. Lin NU, Dieras V, Paul D, et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol. 2007;25(Suppl. 18):1012
  40. Spielmann MRH, Humblet Y, et al. 3-year follow-up ofTrastuzumab following adjuvant chemotherapy in nodepositive HER2-positive breast-cancer patients: results of the PACS-04 trial. Breast Cancer Res Treatment. 2007;106(Supp1):Abstr 72
  41. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684
  42. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol. 2007;25(Suppl. 18):abstr 512
  43. Slamon WE, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treatment. 2005;94(Suppl. 1):S5
  44. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672
  45. Slamon D EW, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AT/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Breast Cancer Research and Treatment. 2006;100(Supp1):abstr 52
  46. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2006;369(9555):29–36
  47. Editorial TL. Herceptin and early breast cancer: a moment for caution. Lancet. 2005;366(9498):1673
  48. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809–820
  49. Sledge GWONA, Thor A, Kahanic SP, Zander PJ, Davidson N. Group ftECO Adjuvant trastuzumab: long-term results of E2198. Breast Cancer Res Treatment. 2006;100(Suppl. 1):Abstr 2075
  50. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 1998;17(17):2235–2249
  51. Robert NL-JB, Asmar L, Belt R, et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treatment. 2002;76(Suppl. 1):S35
  52. Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90(18):1361–1370
  53. Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354(20):2103–2111
  54. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100(1):14–20
  55. Slamon DJMJ, Robert N, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analysis determined by molecular subtypes of the disease. Breast Cancer Res Treatment. 2007;106(Suppl. 1):S5;abstr 13
  56. Rayson D, Richel D, Chia S, Jackisch C, van derVegt S, Suter T. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol. 2008;19(9):1530–1539
  57. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676–3685
  58. Gianni L, Semiglazov V, Manikhas GM, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumour and safety analysis. J Clin Oncol. 2007;25(Suppl. 18):532
  59. Johnston SR, Martin LA, Leary A, Head J, Dowsett M. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol. 2007;106(1–5):180–186
  60. Kaufman BM, Mackey J, Clemens M, et al. Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausalwomen with HER2-positive, hormone-dependent metastatic breast cancer. Ann Oncol. 2006;17(Suppl. 9):LBA2
  61. Smith I. Which tools can I use in daily clinical practice to improve tailoring of treaatment for breast cancer? Treatment decision-making in advanced disease. Ann oncol. 2008;19(Suppl.):vii51–vii57

PII: S0959-8049(08)00837-X

doi: 10.1016/j.ejca.2008.10.013

European Journal of Cancer
Volume 45, Issue 1 , Pages 12-18 , January 2009

Article Tools